For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Acquired in-process research and development | - | 2,129,491.5* | ||
| Research and development | 749,813 | 92,042.5* | ||
| General and administrative | 1,533,926 | 931,954* | ||
| Total operating expenses | 2,283,739 | 3,153,488 | ||
| Loss from operations | -2,283,739 | -3,153,488* | ||
| Interest income, net and other | 59,111 | 23,868* | ||
| Loss from continuing operations | -2,224,628 | - | ||
| Net loss | -2,224,628 | -3,129,620 | ||
| Loss from continuing operation, total | -2,224,628 | - | ||
| Loss from continuing operations attributable to common stockholders | -2,224,628 | -3,129,620 | ||
| Basic EPS | -4.18 | -32.275 | ||
| Diluted EPS | -4.18 | -32.275 | ||
| Basic Average Shares | 531,968 | 96,967 | ||
| Diluted Average Shares | 531,968 | 96,967 | ||
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)